

## Complete Summary

---

### TITLE

Lipid management in adults: percentage of patients on a lipid lowering medication who have a fasting lipid panel every three to twelve months.

### SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Jul. 72 p. [109 references]

## Brief Abstract

### DESCRIPTION

This measure assesses the percentage of patients on a lipid lowering medication who have a fasting lipid panel every three to twelve months.

### RATIONALE

The priority aim addressed by this measure is to improve the percentage of patients on lipid lowering medication who receive regular follow-up care for lipid disorder.

### PRIMARY CLINICAL COMPONENT

Dyslipidemia; bile acid sequestrant (BAS); fibric acids; niacin; statin; fasting lipid panel (total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides, low-density lipoprotein [LDL]-cholesterol)

### DENOMINATOR DESCRIPTION

Total number of patients who are on lipid lowering medication whose records are reviewed (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

### NUMERATOR DESCRIPTION

Number of patients on lipid lowering medication who have a fasting lipid panel (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

## Evidence Supporting the Measure

### PRIMARY MEASURE DOMAIN

Process

### SECONDARY MEASURE DOMAIN

Not applicable

### EVIDENCE SUPPORTING THE MEASURE

A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

### NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Lipid management in adults.](#)

## Evidence Supporting Need for the Measure

### NEED FOR THE MEASURE

Unspecified

## State of Use of the Measure

### STATE OF USE

Current routine use

### CURRENT USE

Internal quality improvement

## Application of Measure in its Current Use

### CARE SETTING

Physician Group Practices/Clinics

### PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

### LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

#### TARGET POPULATION AGE

Age 20 to 75 years

#### TARGET POPULATION GENDER

Either male or female

#### STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

### Characteristics of the Primary Clinical Component

#### INCIDENCE/PREVALENCE

See "Burden of Illness" field.

#### ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

#### BURDEN OF ILLNESS

Heterozygous familial hypercholesterolemia affects 1 in 500 persons in the United States with the risk of death from coronary artery disease increased almost four fold between the ages of 20 and 74. (Myocardial infarction leading to sudden death often occurs in these men in their 30's or 40's, and by age 50, 80 percent of males have ischemic heart disease.) Without intervention, approximately 50-75 percent of men with heterozygous familial hypercholesterolemia will have a myocardial infarction by age 60. Thompson showed the prevalence of coronary disease in men at age 35 equalled that in women at age 40 in contrast to the typical 10 year lag between men and women (Thompson, et al. Arteriosclerosis, 1989).

#### EVIDENCE FOR BURDEN OF ILLNESS

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Jul. 72 p. [109 references]

#### UTILIZATION

Unspecified

#### COSTS

Unspecified

## Institute of Medicine National Healthcare Quality Report Categories

### IOM CARE NEED

Living with Illness

### IOM DOMAIN

Effectiveness

## Data Collection for the Measure

### CASE FINDING

Users of care only

### DESCRIPTION OF CASE FINDING

All patients age 20 to 75 who are dyslipidemic and on a lipid lowering medication

The preferred way to collect these data:

- All patients 20 to 75 years old who are dyslipidemic and on a lipid lowering medication could be identified. This would include patients with Hypercholesterolemia (high low-density lipoprotein [LDL], normal triglycerides and high-density lipoprotein [HDL]), combined Hyperlipidemia (high LDL and triglycerides), Hypertriglyceridemia and Hypercholesterolemia (with isolated low HDL) who are on a lipid lowering medication.
- Each medical group would select at random 20 patients for measurement each month to determine if a fasting lipid panel has been done.

Data on 20 patients are collected monthly and reported quarterly.

### DENOMINATOR SAMPLING FRAME

Patients associated with provider

### DENOMINATOR (INDEX) EVENT

Clinical Condition  
Therapeutic Intervention

### DENOMINATOR INCLUSIONS/EXCLUSIONS

#### Inclusions

Total number of patients who are on lipid lowering medication\* whose records are reviewed

\*Patients age 20 to 75 years old who are dyslipidemic on a lipid lowering medication\*\*, including: bile acid sequestrant (BAS), fibric acids, niacin, statin.

\*\*Refer to Annotation Appendix C, "Drug Companion Document-Treatment Options for Dyslipidemia" in the original measure documentation for a complete listing of lipid lowering medications.

Exclusions  
Unspecified

## NUMERATOR INCLUSIONS/EXCLUSIONS

### Inclusions

Number of patients on lipid lowering medication who have a fasting lipid panel\*

\*Of the patients in the denominator, those who have had a fasting lipid panel in the past 3-12 months (measurement of total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides and calculated low-density lipoprotein [LDL]-cholesterol after a 12-hour fasting period).

Current Procedure Terminology (CPT-4) codes: 83718 (lipoprotein, direct measurement: HDL-cholesterol), 83719 (very low-density lipoprotein [VLDL]), 83721 (LDL), 80061 (lipid profile)

Exclusions  
Unspecified

## DENOMINATOR TIME WINDOW

Time window is a fixed period of time

## NUMERATOR TIME WINDOW

Fixed time period

## DATA SOURCE

Administrative data  
Medical record

## LEVEL OF DETERMINATION OF QUALITY

Individual Case

## PRE-EXISTING INSTRUMENT USED

Unspecified

## Computation of the Measure

## SCORING

Rate

## INTERPRETATION OF SCORE

Better quality is associated with a higher score

## ALLOWANCE FOR PATIENT FACTORS

Unspecified

## STANDARD OF COMPARISON

Internal time comparison

## Evaluation of Measure Properties

## EXTENT OF MEASURE TESTING

Unspecified

## Identifying Information

## ORIGINAL TITLE

Percentage of patients on a lipid lowering medication who have a fasting lipid panel every three to twelve months.

## MEASURE COLLECTION

[Lipid Management in Adults Measures](#)

## DEVELOPER

Institute for Clinical Systems Improvement

## ADAPTATION

Measure was not adapted from another source.

## RELEASE DATE

2003 Jul

## MEASURE STATUS

This is the current release of the measure.

## SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Jul. 72 p. [109 references]

#### MEASURE AVAILABILITY

The individual measure, "Percentage of patients on a lipid lowering medication who have a fasting lipid panel every three to twelve months," is published in "Health Care Guideline: Lipid Management in Adults." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org); e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

#### NQMC STATUS

This NQMC summary was completed by ECRI on April 28, 2004.

#### COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

© 2004 National Quality Measures Clearinghouse

Date Modified: 11/1/2004

